查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601611

病毒疫苗市場規模、佔有率、預測、趨勢分析：按形式類型、給藥途徑、方法、適應症、包裝 - 2031 年全球預測

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form Type, Route of Administration, Approach, Indication, Packaging - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 239 Pages | 商品交期: 最快1-2個工作天內

價格

到2031年，病毒疫苗市場預計將達到641.8億美元，2024年至2031年的複合年增長率為9.3%。

病毒疫苗或病毒載體疫苗使用病毒載體將遺傳物質引入宿主體內，誘發免疫反應，對抗或預防病毒感染。

該市場的成長是由政府對免疫計劃的興趣日益濃厚、疫苗管理技術進步以及在手術和治療中使用滅活疫苗推動的。然而，疫苗開發成本高、生產疫苗所需時間長，限制了市場的成長。

此外，對治療性疫苗的日益關注、疫苗中佐劑的使用增加、新興市場的增長前景以及穩定且節能的超低溫冰箱的開發預計將為市場參與者帶來增長機會。然而，產品召回和疫苗取得不足是影響市場成長的主要挑戰。

該報告還對主要公司的產品組合和地理分佈以及過去三到四年採取的主要成長策略進行了全面評估。作為最近的趨勢，病毒疫苗市場經歷了幾次有機和無機的策略發展。本報告介紹的主要公司概況包括Pfizer Inc.（美國）、GlaxoSmithKline plc（英國）、AstraZeneca plc （英國）、CSL Limited（澳洲）、Merck & Co., Inc. （美國）、Sanofi （法國）、Sinovac Biotech Ltd.（中國）、Moderna, Inc.（美國）、Valneva SE（法國）、Dynavax Technologies Corporation（美國）、EMERGENT BIOSOLUTIONS INC.（美國）、Johnson &Johnson（美國）、Bharat Biotech Ltd.（印度）、Serum Institute.（印度）、Serum Institute of India Pvt.（印度）。

疫苗中佐劑的使用增加

傳統的減毒疫苗已被證明對多種適應症有效，包括天花、麻疹和小兒麻痺。然而，這些疫苗通常會帶來副作用，例如發燒、皮疹和疫苗引起的感染。此外，規模化生產和疫苗穩定性問題也是重大挑戰。為了解決這些問題，人們開發了佐劑疫苗來刺激強大的免疫反應。

佐劑疫苗僅含有一小部分病原體，可降低免疫原性並最大限度地減少副作用。疫苗中的佐劑發揮多種作用，包括：

  • 透過施用純形式的抗原來引發針對抗原的免疫反應。
  • 有利於一次性接種疫苗並降低疫苗接種成本。
  • 增強免疫功能低下患者的免疫反應。

直到最近，含鋁佐劑仍被認為是與其他佐劑進行比較的黃金標準。然而，最近的進展改善了這些佐劑的物理、化學和生物特性，減少了人類的過敏反應、致癌性、致畸性和毒性。輔助系統也進行了各種改進。例如，基於水包油乳液的佐劑因其有效且有前景的結果而被開發供人類使用。此外，病毒體疫苗專為流感治療而設計，可提供功效、品質和持久的免疫反應。正在進行的研究重點是選擇最佳佐劑，例如經典佐劑、免疫刺激劑或其組合，以提高疫苗功效。因此，佐劑研究和利用的進步正在為疫苗製造商創造新的成長機會。

在本報告調查的形式中，冷凍乾燥疫苗領域預計將在2024年創下病毒疫苗市場最高複合年增長率11.1%。冷凍乾燥病毒疫苗透過冷凍乾燥過程儲存，可去除多餘的水分，提高穩定性，延長保質期並方便運輸。這些疫苗通常用於預防黃熱病、麻疹、腮腺炎、德國麻疹和其他病毒性疾病等感染，並具有提高穩定性和運輸能力等優點。

在本報告調查的疫苗類型中，病毒載體疫苗領域預計在2024年病毒疫苗市場的複合年增長率最高為17%。病毒載體疫苗使用基因改造病毒將遺傳物質引入細胞，促使它們產生觸發免疫反應的病毒蛋白。這些疫苗具有多種優勢，包括強大的免疫反應、快速開發和可擴展性、廣泛的功效以及多價疫苗的可能性。

在本報告調查的方法中，預防性疫苗領域預計將在 2024 年創下病毒疫苗市場最高複合年增長率。這一增長是由慢性病和傳染病患者病率不斷上升、公眾疫苗接種意識增強以及免疫規劃擴大等因素所推動的。例如，2024 年 2 月，印度聯邦財政和企業事務部長在 Viksit Bharat 2047 運動下提出了一項疫苗接種計劃，旨在預防 9 至 14 歲女孩患子宮頸癌。

在本報告調查的適應症中，癌症領域預計將在2024年創下病毒疫苗市場最高的複合年增長率，達到24.1%。據GLOBOCAN稱，2022年將有2,000萬新報告癌症病例，預計2030年將增加至2,410萬例。癌症盛行率的不斷上升凸顯了對減少人類痛苦和經濟負擔的預防技術的需求。疫苗在癌前病變和癌症的一級預防以及減少已接受治療的患者復發的二級預防中發揮著重要作用。

在本報告調查的給藥途徑中，預計到 2024 年，肌肉注射將佔據病毒疫苗市場的最大佔有率。優選肌肉注射，即將疫苗注射到患者的肌肉中，因為其安全性、耐受性、與各種類型疫苗的相容性以及引發強烈免疫反應的能力。

在本報告研究的包裝類型中，小瓶包裝預計將在 2024 年病毒疫苗市場達到最高複合年增長率。塑膠或玻璃瓶是用於包裝液體或粉末藥物的小容器。小瓶為病毒疫苗提供了一個保護環境，透過保護它們免受水分、光線和污染等外部因素的影響，幫助保持穩定性和有效性。

在本報告研究的地區中，亞太地區的病毒疫苗市場複合年增長率預計最高，達 10.2%。促成這一增長的主要因素包括傳染患者病率的增加、公眾對疫苗和免疫接種意識的提高、政府舉措、高醫療保健支出以及可支配收入的增加。例如，2024年4月，沃克哈特醫院（印度）針對所有年齡層的人啟動了免疫計劃，以強調疫苗接種的重要性。

調查範圍：

病毒疫苗市場：依形式

  • 液體疫苗
  • 冷凍乾燥疫苗

病毒疫苗市場：依疫苗類型劃分

  • 次單位疫苗和結合疫苗
  • 活疫苗
  • 滅活​​疫苗
  • mRNA疫苗
  • 病毒載體疫苗
  • 類毒素疫苗
  • 聯合疫苗

病毒疫苗市場：依給藥途徑劃分

  • 肌肉注射 (IM)
  • 皮下注射 (SC)
  • 口頭
  • 其他給藥途徑

（其他病毒包括諾羅病毒、DNA病毒）

病毒疫苗市場：依方法劃分

  • 預防性疫苗
  • 治療性疫苗

病毒疫苗市場：依適應症劃分

  • 流感
  • 人類乳突病毒 (HPV)
  • 輪狀病毒
  • 小兒麻痺
  • 肝炎
  • 癌症
  • 其他適應症

（其他適應症包括水痘、帶狀皰疹疫苗、小球藻、嚴重急性呼吸道症候群、狂犬病等）

病毒疫苗市場：依包裝劃分

  • 小瓶
  • 預灌封注射器

病毒疫苗市場：依地區劃分

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 瑞士
    • 愛爾蘭
    • 丹麥
    • 比利時
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 中東/非洲

目錄

第一章簡介

第二章研究方法

第 3 章執行摘要

第 4 章市場洞察

  • 市場概覽
  • 影響市場成長的因素
    • 促進因素
      • 政府對疫苗接種計劃的興趣增加
      • 疫苗接種技術的進步
    • 阻礙因素
      • 疫苗開發成本高
      • 延長疫苗生產時間
    • 機會
      • 越來越多關注治療性疫苗
      • 疫苗中佐劑的使用增加
      • 新興市場的成長前景
    • 課題
      • 產品系列
      • 無法充分取得疫苗
    • 主要趨勢
      • 個人化疫苗與疫苗組學
      • 媒體與大眾對疫苗接種的認識
  • 監理分析
  • 價格分析
  • 波特五力分析
  • 管道分析

第五章病毒疫苗市場評估：依形式

  • 摘要
  • 液體病毒疫苗
  • 冷凍乾燥病毒疫苗

第六章病毒疫苗市場：依疫苗類型

  • 摘要
  • mRNA疫苗
  • 次單位疫苗和結合疫苗
  • 活疫苗
  • 滅活​​疫苗
  • 病毒載體/疫苗
  • 聯合疫苗

第七章病毒疫苗市場評估：依給藥途徑

  • 摘要
  • 肌肉注射 (IM)
  • 皮下注射 (SC)
  • 口頭
  • 其他給藥途徑

第八章病毒疫苗市場評估：依方法

  • 摘要
  • 預防性疫苗
  • 治療性疫苗

第九章病毒疫苗市場評估：依適應症

  • 摘要
  • 流感
  • 人類乳突病毒 (HPV)
  • 輪狀病毒
  • 小兒麻痺
  • 肝炎
  • 癌症
  • 其他適應症

第十章病毒疫苗市場評估：依包裝

  • 摘要
  • 小瓶
  • 預灌封注射器

第十一章冠狀病毒疾病

  • 新冠肺炎 (COVID-19)：概述
  • 冠狀病毒流行情況
  • 新冠肺炎 (COVID-19) 市場評估

第十二章病毒疫苗市場評估：按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 瑞士
    • 愛爾蘭
    • 丹麥
    • 比利時
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 中東/非洲

第十三章競爭態勢

  • 簡介
  • 主要成長策略
  • 競爭基準測試
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市佔率分析

第十四章公司簡介

  • Pfizer Inc.
  • Glaxo Smith Kline plc
  • AstraZeneca plc
  • CSL Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Johnson & Johnson
  • Emergent Biosolutions Inc.
  • Bharat Biotech Ltd.
  • Sinovac Biotech Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Dynavax Technologies Corporation
  • Valneva SE

第15章附錄

Product Code: MRHC - 1041237

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031

According to a new market research report, 'Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031', published by Meticulous Research(R), the viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031.

Viral vaccines or viral vector vaccines use a viral vector to deliver genetic material into the host to elicit an immune response to fight or protect against viral infections.

The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.

Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market's growth.

The report also includes an extensive assessment of the leading players' product portfolio and geographic presence and the key growth strategies adopted by them over the past three to four years. In recent years, the viral vaccines market has witnessed several organic and inorganic strategic developments. The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).

Increasing Use of Adjuvants in Vaccines

Conventional live-attenuated vaccines have proven effective for various indications, such as smallpox, measles, and polio, in most cases. However, these vaccines often come with side effects, including fever, rashes, and vaccine-derived infections. Additionally, large-scale production and issues related to vaccine consistency present significant challenges. To address these issues, adjuvant vaccines, which stimulate robust immune responses, were developed.

Adjuvant vaccines contain only a small part of the pathogen, which helps reduce immunogenicity and minimizes side effects. Adjuvants in vaccines serve various purposes, including:

  • Initiating the immune response to antigens by delivering them in their native form.
  • Facilitating single-step vaccination, thereby reducing vaccination costs.
  • Enhancing immune responses in immunocompromised individuals.

Until recently, aluminum-containing adjuvants were considered the gold standard for comparing other adjuvants. However, recent advancements have improved the physical, chemical, and biological properties of these adjuvants, reducing hypersensitivity reactions, carcinogenicity, teratogenicity, and toxicity in humans. Various modifications to adjuvant systems have also been made. For instance, oil-in-water emulsion-based adjuvants have been developed for human use due to their effective and promising results. Additionally, virosome vaccines have been specifically designed for influenza treatment, offering effectiveness, quality, and long-lasting immune responses. Ongoing research is focused on selecting the best adjuvants-whether classical adjuvants, immunostimulants, or combinations-to enhance vaccine efficacy. As a result, advancements in adjuvant research and utilization present new growth opportunities for vaccine manufacturers.

The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (mRNA Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Influenza, Human Papilloma Virus (HPV), Rotavirus, Poliomyelitis (Polio), Hepatitis, Cancer, and Other Indications), Packaging (Vials, Prefilled Syringes) and Geography.

Among the forms studied in this report, in 2024, the lyophilized vaccines segment is slated to register the highest CAGR of 11.1% of the viral vaccines market. Lyophilized viral vaccines are preserved through a freeze-drying process that removes excess water, enhancing their stability, extending shelf life, and making transportation easier. These vaccines are commonly used to prevent infections such as yellow fever, measles, mumps, rubella, and other viral diseases, offering advantages such as improved stability and transportability.

Among the vaccine types studied in this report, in 2024, the viral vector vaccines segment is slated to register the highest CAGR of 17% of the viral vaccines market. Viral vector vaccines use modified viruses to deliver genetic material into cells, prompting them to produce viral proteins that trigger an immune response. These vaccines offer several benefits, including a strong immune response, rapid development and scalability, broad effectiveness, and the potential for creating multivalent vaccines.

Among the approaches studied in this report, in 2024, the preventive vaccines segment is slated to register the highest CAGR of the viral vaccines market. This growth is driven by factors such as the increasing prevalence of chronic and infectious diseases, rising public awareness of immunization, and the expansion of immunization programs. For instance, in February 2024, the Union Minister for Finance & Corporate Affairs of India proposed a vaccination program under the Viksit Bharat by 2047 campaign aimed at preventing cervical cancer in girls aged 9 to 14.

Among the indications studied in this report, in 2024, the cancer segment is slated to register the highest CAGR of 24.1% of the viral vaccines market. Cancer prevalence is rising globally; according to GLOBOCAN, 20.0 million new cancer cases were reported in 2022, with this number projected to increase to 24.1 million by 2030. The growing prevalence of cancer highlights the need for preventive techniques to reduce human suffering and financial burdens. Vaccines play a crucial role in first-line prevention of premalignant conditions and cancer, as well as in secondary prevention for patients who have undergone curative treatments to reduce recurrence.

Among the routes of administration studied in this report, in 2024, the intramuscular segment is expected to account for the largest share of the viral vaccines market. The IM route, which involves administering vaccines into a patient's muscles, is preferred due to its ability to elicit a strong immune response, along with its safety, tolerability, and compatibility with various vaccine types.

Among the packaging types studied in this report, in 2024, the vials segment is slated to register the highest CAGR of the viral vaccines market. Vials, made from plastic or glass, are small containers used to package liquid or powdered medications. They provide a protective environment for viral vaccines, helping to maintain stability and efficacy by shielding the vaccines from external factors like moisture, light, and contamination.

Among the regions studied in this report, Asia-Pacific is slated to register the highest CAGR of 10.2% of the viral vaccines market. This growth is primarily attributed to the increasing prevalence of infectious diseases, growing public awareness of vaccines and immunization, government initiatives, high healthcare expenditure, and rising disposable incomes. For instance, in April 2024, Wockhardt Hospitals (India) launched an immunization program aimed at people of all age groups to emphasize the importance of vaccination.

Scope of the Report:

Viral Vaccines Market-by Form

  • Liquid Vaccines
  • Lyophilized Vaccines

Viral Vaccines Market-by Vaccine Type

  • Subunit & Conjugate Vaccines
  • Live-attenuated Vaccines
  • Inactivated Vaccines
  • mRNA Vaccines
  • Viral Vector Vaccines
  • Toxoid Vaccines
  • Combination Vaccines

Viral Vaccines Market-by Route of Administration

  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Oral
  • Other Routes of Administration

(Other virus types include norovirus and DNA viruses)

Viral Vaccines Market-by Approach

  • Preventive Vaccines
  • Therapeutic Vaccines

Viral Vaccines Market-by Indication

  • Influenza
  • Human Papilloma Virus (HPV)
  • Rotavirus
  • Poliomyelitis (Polio)
  • Hepatitis
  • Cancer
  • Other Indications

(Other indications include varicella, herpes zoster vaccines, chlorella, severe acute respiratory syndrome, and rabies diseases)

Viral Vaccines Market-by Packaging

  • Vials
  • Prefilled Syringes

Viral Vaccines Market-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Switzerland
    • Ireland
    • Denmark
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders From The Industry
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Increasing Government Focus on Immunization Programs
      • 4.2.1.2. Technological Advancements in Vaccine Administration
    • 4.2.2. Restraints
      • 4.2.2.1. High Costs of Vaccine Development
      • 4.2.2.2. Long Timelines of Vaccine Manufacturing
    • 4.2.3. Opportunities
      • 4.2.3.1. Growing Focus on Therapeutic Vaccines
      • 4.2.3.2. Increasing Use of Adjuvants in Vaccines
      • 4.2.3.3. Growth Prospects in Emerging Markets
    • 4.2.4. Challenges
      • 4.2.4.1. Product Recalls
      • 4.2.4.2. Inadequate Access to Vaccines
    • 4.2.5. Key Trends
      • 4.2.5.1. Personalized Vaccines and Vaccinomics
      • 4.2.5.2. Media and Public Awareness Regarding Immunization
  • 4.3. Regulatory Analysis
  • 4.4. Pricing Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Buyers
    • 4.5.2. Bargaining Power of Suppliers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Pipeline Analysis

5. Viral Vaccines Market Assessment-by Form

  • 5.1. Overview
  • 5.2. Liquid Viral Vaccines
  • 5.3. Lyophilized Viral Vaccines

6. Viral Vaccines Market-by Vaccine Type

  • 6.1. Overview
  • 6.2. mRNA Vaccines
  • 6.3. Subunit & Conjugate Vaccines
  • 6.4. Live-attenuated Vaccines
  • 6.5. Inactivated Vaccines
  • 6.6. Viral Vector Vaccines
  • 6.7. Combination Vaccines

7. Viral Vaccines Market Assessment-by Route of Administration

  • 7.1. Overview
  • 7.2. Intramuscular (IM)
  • 7.3. Subcutaneous (SC)
  • 7.4. Oral
  • 7.5. Other Routes of Administration

8. Viral Vaccines Market Assessment-by Approach

  • 8.1. Overview
  • 8.2. Preventive Vaccines
  • 8.3. Therapeutic Vaccines

9. Viral Vaccines Market Assessment-by Indication

  • 9.1. Overview
  • 9.2. Influenza
  • 9.3. Human Papillomavirus (HPV)
  • 9.4. Rotavirus
  • 9.5. Poliomyelitis (Polio)
  • 9.6. Hepatitis
  • 9.7. Cancer
  • 9.8. Other Indications

10. Viral Vaccines Market Assessment-by Packaging

  • 10.1. Overview
  • 10.2. Vials
  • 10.3. Prefilled Syringes

11. Coronavirus Disease

  • 11.1. COVID-19: Overview
  • 11.2. Coronavirus Prevalence
  • 11.3. COVID-19 Market Assessment

12. Viral Vaccines Market Assessment-by Geography

  • 12.1. Overview
  • 12.2. North America
    • 12.2.1. U.S.
    • 12.2.2. Canada
  • 12.3. Europe
    • 12.3.1. Germany
    • 12.3.2. U.K.
    • 12.3.3. France
    • 12.3.4. Italy
    • 12.3.5. Spain
    • 12.3.6. Switzerland
    • 12.3.7. Ireland
    • 12.3.8. Denmark
    • 12.3.9. Belgium
    • 12.3.10. Rest of Europe
  • 12.4. Asia-Pacific
    • 12.4.1. Japan
    • 12.4.2. China
    • 12.4.3. India
    • 12.4.4. South Korea
    • 12.4.5. Rest of Asia-Pacific
  • 12.5. Latin America
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Middle East & Africa

13. Competitive Landscape

  • 13.1. Introduction
  • 13.2. Key Growth Strategies
  • 13.3. Competitive Benchmarking
  • 13.4. Competitive Dashboard
    • 13.4.1. Industry Leaders
    • 13.4.2. Market Differentiators
    • 13.4.3. Vanguards
    • 13.4.4. Emerging Companies
  • 13.5. Market Share Analysis

14. Company Profiles

  • 14.1. Pfizer Inc.
  • 14.2. Glaxo Smith Kline plc
  • 14.3. AstraZeneca plc
  • 14.4. CSL Limited
  • 14.5. Merck & Co., Inc.
  • 14.6. Moderna, Inc.
  • 14.7. Johnson & Johnson
  • 14.8. Emergent Biosolutions Inc.
  • 14.9. Bharat Biotech Ltd.
  • 14.10. Sinovac Biotech Ltd.
  • 14.11. Sanofi
  • 14.12. Serum Institute of India Pvt. Ltd.
  • 14.13. Dynavax Technologies Corporation
  • 14.14. Valneva SE

15. Appendix

  • 15.1. Available Customization
  • 15.2. Related Reports

LIST OF TABLES

  • Table 1 Estimated Number of Malaria Cases in Regions with Emerging Countries, 2022 (in Thousands)
  • Table 2 Number of People Living with HIV, by Region, 2022 (in Million)
  • Table 3 Key Government Agencies Regulating Vaccines
  • Table 4 Average Selling Prices of Key Vaccines, by Region (USD/UNIT)
  • Table 5 Viral Vaccines: Pipeline Analysis
  • Table 6 Global Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 7 Global Liquid Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 8 Companies Offering Lyophilized Viral Vaccines
  • Table 9 Global Lyophilized Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 11 Companies Offering mRNA Vaccines
  • Table 12 Global mRNA Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Companies Offering Subunit and Conjugate Vaccines
  • Table 14 Global Subunit & Conjugate Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Companies Offering Live-Attenuated Vaccines
  • Table 16 Global Live-Attenuated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Key Companies Offering Inactivated Vaccines
  • Table 18 Global Inactivated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global Viral Vector Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Key Companies Offering Combination Vaccines
  • Table 21 Global Combination Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 23 Intramuscular Sites For Vaccine Administration, by Age Group
  • Table 24 Global Intramuscular Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Subcutaneous Sites For Vaccine Administration, by Age Group
  • Table 26 Global Subcutaneous Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Key Companies Offering Oral Viral Vaccines
  • Table 28 Global Oral Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Viral Vaccines Market for Other Routes of Administration, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 31 Global Preventive Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global Therapeutic Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 34 Global Viral Vaccines Market For Influenza, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Viral Vaccines Market For Human Papillomavirus (HPV), by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Viral Vaccines Market For Rotavirus, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Viral Vaccines Market For Poliomyelitis, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Viral Vaccines Market For Hepatitis, by Country/Region, 2022-2031 (USD Million)
  • Table 39 Global NUMBER of New Cancer Cases, 2022-2030
  • Table 40 Global Viral Vaccines Market For Cancer, by Country/Region, 2022-2031 (USD Million)
  • Table 41 Global Viral Vaccines Market For Other Indications, by Country/Region, 2022-2031 (USD Million)
  • Table 42 Global Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 43 Global Viral Vaccine Vials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 44 Global Prefilled Viral Vaccine Syringes Market, by Country/Region, 2022-2031 (USD Million)
  • Table 45 COVID-19: Overview
  • Table 46 Coronavirus Confirmed Cases, by Region (As of April 2024)
  • Table 47 Global Viral Vaccines Market FOR COVID-19, by Country/Region, 2022-2031 (USD Million)
  • Table 48 Global Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 49 North America: Viral Vaccines Market, by Country, 2022-2031 (USD Million)
  • Table 50 North America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 51 North America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 52 North America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 53 North America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 54 North America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 55 North America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 56 U.S.: Accelerated Approval Dates of Vaccines By The U.S. FDA
  • Table 57 U.S.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 58 U.S.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 59 U.S.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 60 U.S.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 61 U.S.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 62 U.S.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 63 Canada: Influenza Cases, 2023-2024, Week 1-34
  • Table 64 Canada: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 65 Canada: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 66 Canada: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 67 Canada: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 68 Canada: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 69 Canada: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 70 Europe: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 71 Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 72 Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 73 Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 74 Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 75 Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 76 Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 77 Germany: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 78 Germany: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 79 Germany: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 80 Germany: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 81 Germany: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 82 Germany: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 83 U.K.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 84 U.K.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 85 U.K.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 86 U.K.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 87 U.K.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 88 U.K.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 89 France: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 90 France: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 91 France: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 92 France: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 93 France: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 94 France: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 95 Italy: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 96 Italy: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 97 Italy: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 98 Italy: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 99 Italy: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 100 Italy: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 101 Spain: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 102 Spain: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 103 Spain: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 104 Spain: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 105 Spain: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 106 Spain: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 107 Switzerland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 108 Switzerland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 109 Switzerland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 110 Switzerland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 111 Switzerland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 112 Switzerland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 113 Ireland: Number of Infectious Diseases Notifications (2019-2023)
  • Table 114 Ireland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 115 Ireland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 116 Ireland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 117 Ireland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 118 Ireland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 119 Ireland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 120 Denmark: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 121 Denmark: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 122 Denmark: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 123 Denmark: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 124 Denmark: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 125 Denmark: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 126 Belgium: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 127 Belgium: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 128 Belgium: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 129 Belgium: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 130 Belgium: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 131 Belgium: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 132 Rest of Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 133 Rest of Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 134 Rest of Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 135 Rest of Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 136 Rest of Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 137 Rest of Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 138 Asia-Pacific: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 139 Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 140 Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 141 Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 142 Asia-Pacific: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 143 Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 144 Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 145 Japan: Key Macroindicators & Microindicators
  • Table 146 Japan: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 147 Japan: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 148 Japan: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 149 Japan: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 150 Japan: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 151 Japan: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 152 China: Key Macroindicators & Microindicators
  • Table 153 China: Key Immunization Indicators
  • Table 154 China: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 155 China: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 156 China: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 157 China: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 158 China: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 159 China: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 160 India: Key Macroindicators & Microindicators
  • Table 161 India: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 162 India: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 163 India: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 164 India: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 165 India: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 166 India: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 167 South Korea: Key Macroindicators & Microindicators
  • Table 168 South Korea: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 169 South Korea: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 170 South Korea: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 171 South Korea: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 172 South Korea: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 173 South Korea: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 174 Bangladesh: Key Immunization Indicators
  • Table 175 Nepal: Key Immunization Indicators
  • Table 176 Rest of Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 177 Rest of Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 178 Rest of Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 179 Rest of Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 180 Rest of Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 181 Latin America: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 182 Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 183 Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 184 Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 185 Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 186 Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 187 Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 188 Brazil: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 189 Brazil: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 190 Brazil: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 191 Brazil: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 192 Brazil: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 193 Brazil: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 194 Mexico: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 195 Mexico: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 196 Mexico: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 197 Mexico: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 198 Mexico: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 199 Mexico: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 200 Rest of Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 201 Rest of Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 202 Rest of Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 203 Rest of Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 204 Rest of Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 205 Rest of Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 206 Middle East & Africa: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 207 Middle East & Africa: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 208 Middle East & Africa: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 209 Middle East & Africa: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 210 Middle East & Africa: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 211 Middle East & Africa: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 212 Recent Developments, by Company (2021-2024)

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for this Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6 Market Sizing and Growth Forecast Approaches
  • Figure 7 Global Viral Vaccines Market, by Indication, 2024 Vs.2031 (USD Million)
  • Figure 8 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
  • Figure 11 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
  • Figure 12 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
  • Figure 13 Global Viral Vaccines Market, by Geography
  • Figure 14 Impact Analysis of Market Dynamics
  • Figure 15 Porter's Five Forces Analysis
  • Figure 16 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
  • Figure 17 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
  • Figure 18 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
  • Figure 19 Global Viral Vaccines Market, by Approach, 2024 VS. 2031 (USD Million)
  • Figure 20 Global Viral Vaccines Market, by Indication, 2024 VS. 2031 (USD Million)
  • Figure 21 Global Viral Vaccines Market, by Packaging, 2024 VS. 2031 (USD Million)
  • Figure 22 Global Viral Vaccines Market, by GEOGRAPHY, 2024 VS. 2031 (USD Million)
  • Figure 23 North America: Viral Vaccines Market Snapshot
  • Figure 24 Europe: Viral Vaccines Market Snapshot
  • Figure 25 Asia-Pacific: Viral Vaccines Market Snapshot
  • Figure 26 Number of Cases Reported for Dengue, 2019-2023
  • Figure 27 Latin America: Viral Vaccines Market Snapshot
  • Figure 28 Saudi Arabia Viral Vaccination Coverage (2023)
  • Figure 29 Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 30 Viral Vaccines Market: Competitive Benchmarking (Based On Indications)
  • Figure 31 Viral Vaccines Market: Competitive Benchmarking (BASED ON Region)
  • Figure 32 Competitive Dashboard: Viral Vaccines Market
  • Figure 33 Market Share Analysis: Viral Vaccines Market (with Covid-19 Vaccines), 2023
  • Figure 34 Market Share Analysis: Viral Vaccines Market (Without Covid-19 Vaccines), 2023
  • Figure 35 Pfizer Inc.: Financial Snapshot (2023)
  • Figure 36 Glaxo Smith Kline Plc: Financial Overview (2023)
  • Figure 37 AstraZeneca Plc: Financial Overview (2023)
  • Figure 38 CSL LIMITED: Financial Overview (2024)
  • Figure 39 Merck & Co., Inc.: Financial Overview (2023)
  • Figure 40 Moderna, Inc.: Financial Snapshot (2023)
  • Figure 41 Johnson & Johnson: Financial Snapshot (2023)
  • Figure 42 Emergent Biosolutions Inc.: Financial Snapshot (2023)
  • Figure 43 Sinovac Biotech Ltd.: Financial Overview (2023)
  • Figure 44 Sanofi: Financial Overview (2023)
  • Figure 45 Dynavax Technologies Corporation: Financial Snapshot (2023)
  • Figure 46 Valneva SE: Financial Snapshot (2023)